Athersys, Inc.

ATHXQ

US04744L2051

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:55:06 2024-05-10 pm EDT			5-day change	1st Jan Change
0.0042 ^USD	0.00%		-2.33%	-79.00%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Apr. 05	Athersys, Inc. Announces Board Changes	CI

Athersys, Inc. Announces the Resignation of Kenneth H. Traub from the Board of Directors

November 01, 2022 at 08:49 am EDT

On October 31, 2022, Kenneth H. Traub provided notice to Athersys, Inc. that he is resigning
from the Board of Directors of the Company effective immediately.

Latest news about Athersys, Inc.

North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
Athersys, Inc. Announces Board Changes	Apr. 05	CI
Healios Concludes Purchase of Athersys Assets, Becoming Sole Owner of MultiStem IP	Apr. 04	MT
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Healios K.K. completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .	Apr. 02	CI
Final DIP Financing Approved for Athersys, Inc.	Feb. 12	CI
Bidding Procedure Approved for Athersys, Inc.	Feb. 12	CI
Healios' Ischemic Stroke Trial Data Published in JAMA Neurology Journal	Jan. 17	MT
Interim DIP Financing Approved for Athersys, Inc.	Jan. 12	CI
Motion for Joint Administration Approved for Athersys, Inc.	Jan. 11	CI
Healios Steps In as Primary Bidder and Lender for Athersys’s Asset Sale Amidst Bankruptcy	Jan. 10	MT
Motion for Asset Sale Filed by Athersys, Inc.	Jan. 05	CI
Motion for Joint Administration Filed by Athersys, Inc.	Jan. 05	CI
Athersys, Inc. Filed for Bankruptcy	Jan. 04	CI
Healios K.K. entered into an asset purchase agreement to acquire Substantially all assets of ABT Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC for $2.8 million.	Jan. 04	CI
Athersys, Inc. Announces Termination of Maia Hansen as Chief Operating Officer, Effective from December 31, 2023	Dec. 22	CI
Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023	Dec. 22	CI
Athersys, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 16	CI
North American Morning Briefing : Caution Dominates Ahead of CPI Print	Nov. 14	DJ
Athersys Delisted from Nasdaq Risks Bankruptcy; Healios Remains Committed to Drug Development	23-10-20	MT
Athersys, Inc.(OTCPK:ATHX) dropped from S&P TMI Index	23-10-20	CI
Athersys, Inc.(OTCPK:ATHX) dropped from NASDAQ Composite Index	23-10-17	CI
Athersys to Extend Liquidity with Warrant Inducement, Global ARDS License	23-10-16	MT
Athersys Engages Outcome Capital to Assist with Evaluating Strategic Alternatives	23-10-16	CI
Athersys, Inc. Reports Interim Analysis Results of MASTERS-2 Clinical Study with Multistem in Ischemic Stroke	23-10-11	CI

Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ATHERSYS, INC.	-79.00%	259K
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs

Athersys, Inc.

Equities

ATHXQ

US04744L2051

Biotechnology & Medical Research

Athersys, Inc. Announces the Resignation of Kenneth H. Traub from the Board of Directors

Latest news about Athersys, Inc.

Chart Athersys, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs